Dsxs clinical trials
How each study uses dsxs is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2015 | 4 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses dsxs is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque PsoriasisCompletedPhase 3Taro Pharmaceuticals USANCT02618759Written as DSXSHow we know
- Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic DermatitisCompletedPhase 3Taro Pharmaceuticals USANCT02595073Written as DSXSHow we know
- Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque PsoriasisCompletedPhase 2Taro Pharmaceuticals USANCT02601469Written as DSXSHow we know
- Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic DermatitisCompletedPhase 2Taro Pharmaceuticals USANCT02595008Written as DSXSHow we know
- Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp PsoriasisCompletedPhase 3Taro Pharmaceuticals USANCT02932462Written as DSXSHow we know